Universal Ibogaine, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Operating profit has grown by an annual rate -16.74% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.69

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 3 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

2.41

Return on Equity

-85.22%

Price to Book

2.75

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Apr 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-33.33%

6 Months

-50.0%

1 Year

-33.33%

2 Years

0.0%

3 Years

-71.43%

4 Years

-92.86%

5 Years

-93.75%

Universal Ibogaine, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

25.07%

EBIT Growth (5y)

-16.74%

EBIT to Interest (avg)

-1.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.41

Sales to Capital Employed (avg)

0.46

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.75

EV to EBIT

-5.15

EV to EBITDA

-5.15

EV to Capital Employed

1.92

EV to Sales

2.50

PEG Ratio

Dividend Yield

ROCE (Latest)

-26.35%

ROE (Latest)

-85.22%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 75.00% vs 0.00% in Jan 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 66.67% vs 0.00% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.40",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.10",
          "val2": "-0.20",
          "chgp": "150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.10",
          "val2": "-0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-39.30%",
          "val2": "-685.90%",
          "chgp": "64.66%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 130.00% vs -9.09% in Jul 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is 12.50% vs 77.14% in Jul 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.30",
          "val2": "1.00",
          "chgp": "130.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-1.80",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "-0.40",
          "chgp": "-150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.40",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-386.60%",
          "val2": "-1,991.00%",
          "chgp": "160.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ

Apr'25

Jan'25

Change(%)

Net Sales

0.70

0.40

75.00%

Operating Profit (PBDIT) excl Other Income

0.10

-0.20

150.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.10

-0.30

66.67%

Operating Profit Margin (Excl OI)

-39.30%

-685.90%

64.66%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Apr 2025 is 75.00% vs 0.00% in Jan 2025

Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is 66.67% vs 0.00% in Jan 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jul'24

Jul'24

Jul'23

Change(%)

Net Sales

2.30

1.00

130.00%

Operating Profit (PBDIT) excl Other Income

-0.60

-1.80

66.67%

Interest

0.20

Exceptional Items

-1.00

-0.40

-150.00%

Consolidate Net Profit

-2.10

-2.40

12.50%

Operating Profit Margin (Excl OI)

-386.60%

-1,991.00%

160.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jul 2024 is 130.00% vs -9.09% in Jul 2023

Consolidated Net Profit

YoY Growth in year ended Jul 2024 is 12.50% vs 77.14% in Jul 2023

All Annual Results

Company CV

About Universal Ibogaine, Inc.

Universal Ibogaine, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available